LLY

1,107.56

-0.17%↓

JNJ

206.85

+0.04%↑

ABBV

226.94

-2.17%↓

UNH

329.51

+1.13%↑

AZN

93.44

+0.23%↑

LLY

1,107.56

-0.17%↓

JNJ

206.85

+0.04%↑

ABBV

226.94

-2.17%↓

UNH

329.51

+1.13%↑

AZN

93.44

+0.23%↑

LLY

1,107.56

-0.17%↓

JNJ

206.85

+0.04%↑

ABBV

226.94

-2.17%↓

UNH

329.51

+1.13%↑

AZN

93.44

+0.23%↑

LLY

1,107.56

-0.17%↓

JNJ

206.85

+0.04%↑

ABBV

226.94

-2.17%↓

UNH

329.51

+1.13%↑

AZN

93.44

+0.23%↑

LLY

1,107.56

-0.17%↓

JNJ

206.85

+0.04%↑

ABBV

226.94

-2.17%↓

UNH

329.51

+1.13%↑

AZN

93.44

+0.23%↑

Search

PerkinElmer Inc

Avatud

SektorTervishoid

0

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad

By Trading Economics

Sissetulek

-8.6M

47M

Müük

-21M

699M

P/E

Sektori keskmine

54.418

106.172

Aktsiakasum

0.4

Dividenditootlus

0.28

Kasumimarginaal

6.675

Töötajad

11,000

EBITDA

-14M

181M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+10.46% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.28%

2.31%

Järgmine aktsia dividendi kuupäev (ex-date)

16. jaan 2026

Turustatistika

By TradingEconomics

Turukapital

976M

12B

Eelmine avamishind

0

Eelmine sulgemishind

0

Uudiste sentiment

By Acuity

23%

77%

46 / 374 Pingereas Healthcare

PerkinElmer Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. nov 2025, 16:56 UTC

Tulu
Suurimad hinnamuutused turgudel

Alimentation Couche-Tard Shares Rise as 2Q Same-Store Sales Support Profit Growth

25. nov 2025, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. nov 2025, 23:47 UTC

Market Talk

Nikkei May Rise After Stock Gains on Wall Street -- Market Talk

25. nov 2025, 22:39 UTC

Market Talk

Global Equities Roundup: Market Talk

25. nov 2025, 22:39 UTC

Market Talk

Vault Accelerates Exposure to Spot Gold Prices by Six Months -- Market Talk

25. nov 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

25. nov 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

25. nov 2025, 21:38 UTC

Tulu

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25. nov 2025, 21:31 UTC

Market Talk

F&P Healthcare's Share Price Jumps on Profit Guidance Upgrade -- Market Talk

25. nov 2025, 21:27 UTC

Tulu

These Stocks Moved the Most Today: Nvidia, AMD, Alphabet, Abercrombie, Kohl's, Novo Nordisk, Symbotic, and More -- Barrons.com

25. nov 2025, 21:20 UTC

Tulu

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25. nov 2025, 21:18 UTC

Tulu

NIO Stock Drops as EV Maker Posts Narrower Loss -- Barrons.com

25. nov 2025, 21:15 UTC

Tulu

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25. nov 2025, 20:16 UTC

Market Talk

U.S. Natural Gas Falls as December Contract Expires -- Market Talk

25. nov 2025, 18:42 UTC

Market Talk

USDA Backs Mexican Retail Expo to Raise Agricultural Exports -- Market Talk

25. nov 2025, 18:25 UTC

Omandamised, ülevõtmised, äriostud

S&P Global Completes $1.8 Billion Acquisition Of With Intelligence, Strengthening Its Position As A Leader In Private Markets Data & Analytics >SPGI

25. nov 2025, 17:30 UTC

Market Talk

Mexico Posts Record Foreign Direct Investment for Jan-Sep -- Market Talk

25. nov 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

25. nov 2025, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

25. nov 2025, 16:33 UTC

Omandamised, ülevõtmised, äriostud

Eni: Financial Details Weren't Disclosed

25. nov 2025, 16:33 UTC

Omandamised, ülevõtmised, äriostud

Eni: Block OFF-5 Covers an Area of About 17,000 Km Sq. in Water Depths

25. nov 2025, 16:32 UTC

Omandamised, ülevõtmised, äriostud

Eni: Agreement to Become Effective After Approval of Uruguayan Authorities

25. nov 2025, 16:31 UTC

Omandamised, ülevõtmised, äriostud

Eni: Acquisition Is for a 50% Share, Operatorship in Exploration Block OFF-5

25. nov 2025, 16:30 UTC

Omandamised, ülevõtmised, äriostud

Eni Acquires From YPF Shares in the Exploration Block OFF-5 Offshore Uruguay

25. nov 2025, 16:23 UTC

Tulu

This Robotics Stock Soars 40% on Earnings. Here's Why. -- Barrons.com

25. nov 2025, 16:12 UTC

Market Talk

Euro Expected to Rise to $1.25 in 2026: Deutsche Bank -- Market Talk

25. nov 2025, 16:11 UTC

Market Talk

Dollar Could Take One Final Leg Lower in Early 2026 -- Market Talk

25. nov 2025, 16:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. nov 2025, 16:10 UTC

Market Talk

Sterling Could Briefly Rise After Budget -- Market Talk

25. nov 2025, 16:10 UTC

Market Talk

Oil Extends Losses on Ukraine-Russia Peace Deal Hopes -- Market Talk

Võrdlus sarnastega

Hinnamuutus

PerkinElmer Inc Prognoos

Hinnasiht

By TipRanks

10.46% tõus

12 kuu keskmine prognoos

Keskmine 111.1 USD  10.46%

Kõrge 125 USD

Madal 100 USD

Põhineb 11 Wall Streeti analüütiku instrumendi PerkinElmer Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

11 ratings

8

Osta

3

Hoia

0

Müü

Sentiment

By Acuity

46 / 374 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat